Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACTS Harren Jhoti, PhD President & Director Timothy Enns Senior Vice President – Corporate Communications & Marketing ADDRESS US Corporate Office 4140 Dublin Blvd., Suite 200 Dublin, CA 94568 European Office 436 Cambridge Science Park Cambridge, CB4 0QA, UK TELEPHONE US: +1 925.560.0100 UK: +44 (0) 1223 226200 FAX US: +1 925.560.0101 UK: +44 (0) 1223 226201 EMAIL Tim.Enns@astx.com YEAR FOUNDED 1991 Astex Pharmaceuticals, Inc. www.astx.com FINANCIAL SUMMARY • $121 M in unrestricted cash, cash equivalents and marketable securities (current & non-current) as of 6/30/12 • Up to $70.0 M in projected 2012 DACOGEN® royalty revenue • Significant potential product milestones plus future royalty revenues COMPANY PROFILE Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales. For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com. MANAGEMENT Officers James S.J. Manuso, PhD, MBA, Chairman & CEO Harren Jhoti, PhD, President and Director Mohammad Azab, MD, MSc, MBA, Chief Medical Officer Martin Buckland, DPhil, MBA, Chief Business Officer Michael Molkentin, CPA, CFO & Corporate Secretary Senior Management Timothy Enns, Senior Vice President, Corporate Communications and Marketing Lyn Leaper, EPA, PhD, Senior Vice President, Intellectual Property Michael McCullar, PhD, MBA, Senior Vice President, Business Development David Rees, PhD, Senior Vice President, Medicinal Chemistry Neil Thompson, PhD, Senior Vice President, Biology t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Carina Schmidt Chief Executive Officer ADDRESS Fogdevreten 2A 17165 SOLNA SWEDEN TELEPHONE +46 8 508 847 44 Carina Schmidt +46 76 1938 190 EMAIL info@athera.se c.schmidt@athera.se YEAR FOUNDED 2002 Athera Biotechnologies AB www.athera.se FINANCIAL SUMMARY Current shareholders, including Karolinska Development AB (publ), Baltic Sea Foundation and KCIF Coinvestment Fund AB, have invested nearly €17 m in the company. Athera is currently in discussion with investors to raise €10 m to fund the Phase I clinical trial of PC-mAb. Athera plans to partner the program with pharma partners at the end of Phase I trial. Current shareholders have committed to invest up to 1/3rd of the current financing need. COMPANY PROFILE PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine (“PC”), and will be indicated for secondary prevention to improve outcome after acute coronary syndrome (“ACS”). Low endogenous levels of antibodies to phosphorylcholine (“anti-PC”) have been linked to a higher incidence of secondary events as well as a markedly increased mortality after the coronary event. This program is in IND-enabling studies and the IND is expected in 2013. To enhance clinical success by properly selecting the target population, Athera has developed a proprietary companion diagnostic CVDefine® kit to identify patients with low anti-PC levels in need of receiving PC-mAb therapy. The kit is CE-approved. Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory bio-therapeutics and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). The Company initiated its current program, harnessing breakthrough innovations made at the world-renowned Karolinska Institute. The company currently has a proprietary pre-IND program, PC-mAb, supported by an approved proprietary companion diagnostic kit. MANAGEMENT Athera is managed by a team of senior professionals from the pharmaceutical and diagnostics industries in a semi-virtual organization. The core team is led by CEO, Carina Schmidt. Ms. Schmidt has nearly 30 years industrial experience, mainly in business development and management, international marketing and product management within the biotech area. During 15 years she has worked with Pharmacia Biotech/Amersham Biosciences (now GE HealthCare). Later she founded Grasp Bioscience and co-founded BioBusiness Partners Scandinavia, where positions included management consultant, interim CEO and business advisor to several biotech start-ups. In Nov 2011, a new Scientific Advisory Board was formed in Athera, which includes Professors Peter Libby, Maarten Simoons, Lars Wallentin and Ulf de Faire. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31: CONTACTS Dr Bassam Damaj Chairman,
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?